Skip to main content

Table 3 Total mean cost and kaplan-meier estimate per 6-month period (2 years follow-up)

From: Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study

  First site of relapse Secondary site
  Kaplan-Meier estimate (%) Mean cost (€) [95 CI% (bootstrap)] Kaplan-Meier estimate (%) Mean cost (€) [95 CI% (bootstrap)]
0-6 months 78.4% 20 227.39 [15 514.81; 25 342.19] 74.0% 19 141.01 [16 885.80; 21 401.47]
7-12 months 56.6% 18 103.14 [12 747.91; 23 712.83] 52.1% 17 150.03 [14 187.45; 20 139.93]
13-18 months 42.4% 19 173.93 [11 648.09; 27 510.13] 37.1% 14 125.19 [10 996.51; 17 530.20]
19-24 months 36.2% 14 376.70 [7 348.29; 22 564.50] 27.7% 14 774.77 [10 117.74; 20 096.10]